SAN FRANCISCO, CA--(Marketwired - October 22, 2015) - Nutra Pharma Corp. (OTC PINK: NPHC) is pursuing a strategy of over-the-counter sales as it advances a therapeutic pipeline based on cobra toxin. In this interview with The Life Sciences Report, CEO Rik Deitsch elaborates on the plan to grow the company through distribution of Nutra Pharma's pain medications in India, China, Canada and the U.S., and how therapies based on the toxin can address a variety of autoimmune diseases.
The Life Sciences Report: How is Nutra Pharma Corp. being transformed from a company known for making over-the-counter (OTC) pain medications into one that develops therapeutics for pain, HIV and autoimmune diseases?
Rik Deitsch: In early 2003, we were working on a multiple sclerosis drug, an HIV drug and on autoimmune diseases across the board. We started speaking with the FDA in 2009 about an ethical pain therapy that uses microgram doses of cobra venom extract as a neurotoxin, or neuro blocker, for pain and inflammation. We planned to develop oral, topical and injectable versions of this therapy.
The FDA told us our drug qualified as an OTC homeopathic medication because it is derived from a natural product and because the dosage is so small. That allowed us to create our first OTC drugs in 2009-2010.
Now we have seven SKUs (stock keeping units) of Nyloxin, which is our OTC pain treatment for humans, and one SKU of Pet Pain-Away for dogs and cats. We're trying to build the OTC marketplace to fund…
Continue reading this interview: OTC Strategy Supports Cobra Venom Pipeline in Asia and North America: Nutra Pharma's Rik Deitsch
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
Nutra Pharma Corp. is a sponsor of Streetwise Reports. Mr. Deitsch had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Deitsch and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.